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Abstract 
Objectives: Determine the prevalence and identify predictors of hypovitaminosis D in patients with type 2 diabetes 
mellitus (T2DM); 2) correlate vitamin D levels with variables indicative of glycemic control and cardiovascular risk.
Research design and methods: We conducted a cross-sectional study with consecutive patients treated at a Uni-
versity Hospital’s Endocrinology outpatient clinic located at 12°58′S latitude, between October 2012 and November 
2013. Hypovitaminosis D was defined as 25-hydroxyvitamin D < 30 ng/mL (chemiluminescence).
Results: We evaluated 108 patients with mean duration of T2DM of 14.34 ± 8.05 years and HbA1c of 9.2 ± 2.1%. 
Mean age was 58.29 ± 10.34 years. Most were women (72.2%), non-white (89.8%) and had hypertension (75.9%) and 
dyslipidemia (76.8%). Mean BMI was 28.01 ± 4.64 kg/m2; 75.9% were overweight. The prevalence of hypovitaminosis 
D was 62%. In multiple logistic regression, independent predictors of hypovitaminosis D were female gender (OR 3.10, 
p = 0.02), dyslipidemia (OR 6.50, p < 0.01) and obesity (OR 2.55, p = 0.07). In multiple linear regression, only total cho-
lesterol (β = −0.36, p < 0.01) and BMI (β = −0.21, p = 0.04) remained associated with levels of 25-hydroxyvitamin D.
Conclusions: Using currently recommended cutoffs, the prevalence of hypovitaminosis D in Brazilians with T2DM 
was as high as that of non-tropical regions. Female gender, dyslipidemia and obesity were predictors of hypovita-
minosis D. Low levels of 25-hydroxyvitamin D were correlated with high cholesterol and BMI values. Future studies are 
needed to evaluate whether vitamin D replacement would improve these parameters and reduce hard cardiovascular 
outcomes.
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Background
Type 2 diabetes mellitus (T2DM) is a serious and grow-
ing global health problem. In 2013, there were 382 mil-
lion people with diabetes; this number is estimated to 
grow to 592 million by 2035. The highest prevalence rates 
of T2DM are found in developing countries [1].
Hypovitaminosis D is an emerging health problem that 
affects approximately one billion people worldwide [2] 
and might be increasing in frequency [3]. Vitamin D is an 
important hormone for mineral homeostasis and bone 
integrity but also has several pleiotropic effects outside 
the skeleton, including the endocrine system [4]. Recent 
evidence suggests that hypovitaminosis D is common in 
patients with type 2 diabetes mellitus [5].
Hypovitaminosis D may be a neglected cardiovascu-
lar risk factor in patients with type 2 diabetes mellitus 
[6, 7] as vitamin D appears to influence several pathways 
that have been linked to coronary artery disease, such 
as inflammation, vascular calcification, proliferation of 
smooth muscle cells in vascular tissue, myocyte hyper-
trophy, arterial intimal thickness, renin-angiotensin sys-
tem, blood pressure control and insulin resistance [8–10].
To further examine this issue, we sought to determine 
the prevalence of hypovitaminosis D in patients with 
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between vitamin D levels and variables indicative of gly-
cemic control and cardiovascular risk factors.
Methods
Study design
Observational, cross-sectional study. Patients were 
recruited between October 2012 and November 2013.
Study site
Endocrinology outpatient clinic affiliated with the Hospi-
tal of the Federal University of Bahia, located in Salvador, 
Bahia—Brazil (latitude 12°58′S).
Study population
Adult patients with type 2 diabetes mellitus. We did not 
include patients with other types of diabetes, current or 
previous use of vitamin D or multivitamins, pregnant 
women, patients with chronic kidney disease, patients 
with malabsorptive intestinal diseases or status post bari-
atric surgery and patients taking anticonvulsants, drugs 
for the treatment of HIV-AIDS, steroids, rifampicin, 
cholestyramine or orlistat.
Clinical variables
We conducted individualized interviews to collect data 
regarding age, sex, self-reported race, time of diagnosis of 
diabetes, medications in use, and comorbidities. Height 
to the nearest 0.1  cm and weight to the nearest 0.1  kg 
were measured with participants wearing light clothing 
and no shoes. Participants with a body mass index (BMI) 
of 25.0–29.9  kg/m2 were classified as overweight, and 
those with BMI ≥ 30.0 kg/m2 were classified as obese.
Laboratory tests
All patients were asked to stop oral antidiabetic drugs 
and insulin for at least 12 h prior to examination. Patients 
were also asked to refrain from strenuous physical exer-
cise and alcohol intake during 3  days and fast for at 
least 10  h before the serum tests. Blood samples were 
processed for storage within 24  h of collection. Serum 
25-hydroxyvitamin D [25(OH)D] was determined using 
a chemiluminescence kit (DiaSorin LIAISON, MN, USA) 
that recognizes both vitamin D2 and D3 equally. Two lev-
els of controls provided by the manufacturer were run in 
each assay. Inter- and intra-assay coefficients of variation 
based on repeated analysis of a pooled control were 15 
and 13%, respectively. The lower limit of detection of the 
assay was 2.8 ng/mL. Levels of 25-hydroxyvitamin D were 
stratified according to the classification of the Endocrine 
Society 2011 [11]: deficiency (<20  ng/mL), insufficiency 
(20–29  ng/mL) and sufficiency (≥30  ng/mL). Serum 
glycated hemoglobin (HbA1c) was determined using 
HPLC assay on automated analyzer. Serum calcium, 
phosphorus, alkaline phosphatase, parathyroid hormone, 
creatinine, total cholesterol, high-density lipoprotein-
cholesterol (HDL-c), low-density lipoprotein-cholesterol 
(LDL-c), triglycerides, uric acid, ultra-sensible C-reactive 
protein (CRP), glucose concentrations and microalbumi-
nuria were measured using standardized and automated 
assays.
Sample size
Sample size was calculated using the software OpenEpi 
(http://www.openepi.com). The minimum estimated 
sample size to detect a prevalence of hypovitaminosis D 
of 50%, with a precision of 10–95% confidence limits was 
97 patients.
Statistical analyses
Continuous data were presented as mean (±standard 
deviation) or median (inter-quartile range). Categori-
cal variables were summarized using absolute and rela-
tive frequencies and compared using the Chi-square test. 
The relationship between continuous variables indica-
tive of glycemic control and cardiovascular risk factors 
with 25(OH)D levels was evaluated using Pearson’s cor-
relation analyses. Subsequently, variables that were cor-
related with 25(OH)D with p < 0.10 were entered into a 
backward multiple linear regression model (with vitamin 
D level as the dependent variable). A similar strategy 
was used to identify predictors of hypovitaminosis D (a 
binary event) by logistic regression. Variables that were 
associated with hypovitaminosis D (p < 0.10) on univari-
ate analyses were entered into a backward, multivariate 
logistic regression model. A two-sided p value  <0.05 in 
final analyses was deemed significant. All statistical anal-
yses were performed using IBM SPSS for Windows ver-
sion 20.0 (SPSS Inc., Chicago, IL).
Results
Characteristics of the study population
We recruited 108 subjects with type 2 diabetes melli-
tus. Mean age was 58.29 ± 10.34 years and the majority 
were women (72.2%) and non-white (89.8%). The dura-
tion of type 2 diabetes diagnosis was 14.34 ± 8.05 years 
(Table  1); of note, 89.8% of the patients had had type 2 
diabetes mellitus for 5 years or longer.
Most patients were overweight or obese (75%). Mean 
BMI was 28.1 ± 4.6 kg/m2 (Table 1). Women had signifi-
cantly higher BMI values than men (28.57 ± 4.75 kg/m2 
vs. 26.14 ± 3.67 kg/m2; p = 0.01).
Most patients used insulin (72.2%), with a mean dose 
of 0.52  ±  0.28  IU/kg. Only NPH and regular insulin 
were used. Mean doses were: NPH 29.45 ± 14.20 IU (8.0 
to 84.0) and regular insulin 13.74 ±  7.37  IU (4.0–36.0). 
The most commonly used oral antidiabetic agent was 
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metformin (77.8%). The most common combinations 
were metformin plus insulin and metformin plus sulpho-
nylurea (Table 1).
The main comorbidities associated with type 2 diabe-
tes mellitus were hypertension (74.1%) and dyslipidemia 
(76.8%) (Table 1).
Prevalence of and risk factors for hypovitaminosis D
Mean 25(OH)D level was 28.10 ± 9.26 ng/mL. The over-
all prevalence of hypovitaminosis D was 62% (39.8% 
insufficient and 22.2% deficient) (Fig. 1). Hypovitamino-
sis D was more common among women (70.5 vs. 40%, 
female vs. male, p =  0.01), obese (77.1 vs. 54.2%, obese 
vs. non-obese, p = 0.02), dyslipidemic (72.3 vs. 28%, dys-
lipidemic vs. non-dyslipidemic, p < 0.01) and statin users 
(71% vs. 46.1%, users vs. non-users, p =  0.01) (Table  1; 
Fig. 2).
We conducted univariate logistic regression analy-
ses to identify potential predictors of hypovitaminosis 
D [defined by a cutoff of 25(OH)D  <30  ng/mL]. Gen-
der, history of dyslipidemia, statin use and obesity were 
entered into the model but only female gender (OR 3.10, 
p =  0.02), dyslipidemia (OR 6.50, p  <  0.01) and obesity 
(OR 2.55, p =  0.07) emerged as independent predictors 
of hypovitaminosis D (Table 2).
Since the 25(OH)D cutoff used to define vitamin D 
deficiency in our logistic regression analyses might be 
the subject of some controversy, we conducted correla-
tion and multiple linear regression analyses to further 
investigate the association between vitamin D levels, 
glycemic control and cardiovascular risk factors. There 
were no associations between vitamin D levels with 
duration of diabetes, blood pressure, fasting glucose, 
HDL-c, ultra-sensible CRP, uric acid, estimated glo-
merular filtration rate, nor with blood concentrations 
of calcium, phosphorus, alkaline phosphatase and PTH. 
The following variables showed significant inverse lin-
ear correlations with vitamin D levels: BMI (r = −0.20, 
p = 0.04), HbA1c (r = −0.22, p = 0.03), total cholesterol 
(r = −0.39, p  <  0.01), LDL-c (r = −0.32, p  <  0.01), tri-
glycerides (r  =  −0.34, p  <  0.01) and microalbuminuria 
(r = −0.23, p = 0.02) (Table 3; Fig. 3). Since total choles-
terol and LDL-c were highly correlated with each other 
(r  =  0.932, p  <  0.01), we chose to include only one of 
Table 1 Demographic and  clinical characteristics of  108 T2DM patients followed at  an outpatient Endocrinology Clinic 
in Brazil
Italic values indicate statistically significant p-value
T2DM type 2 diabetes mellitus, OAD oral antidiabetic agent
a BMI ≥30 kg/m2
Variable Overall Hypovitaminosis D p
(n = 108) No (n = 41) Yes (n = 67)
Age (years) 58.29 ± 10.34 58.24 ± 9.99 59.19 ± 10.33 0.48
Female gender 78 (72.2%) 23 (56.1%) 55 (82.2%) 0.01
Non-white skin color 97 (89.8%) 39 (95.1%) 58 (86.6%) 0.20
T2DM duration (years) 14.34 ± 8.05 15.38 ± 8.30 14.06 ± 8.30 0.59
BMI 28.01 ± 4.64 27.17 ± 3.87 28.65 ± 4.99 0.13
Obesity a 35 (32.4%) 8 (19.5%) 27 (40.1%) 0.02
Comorbidities Hypertension 82 (74.1%) 30 (73.2%) 52 (77.6%) 0.60
Dyslipidemia 83 (76.8%) 23 (56.1%) 60 (89.5%) <0.01
Insulin use Insulin use 78 (72.2%) 30 (73.2%) 48 (71.6%) 0.86
NPH insulin 77 (71.3%) 29 (70.7%) 48 (71.6%) 0.92
Regular insulin 42 (38.9%) 18 (43.9%) 24 (35.8%) 0.40
Oral antidiabetic agent Sulfonylurea 26 (24.1%) 10 (24.4%) 16 (23.9%) 0.95
Metformin 84 (77.8%) 34 (82.9%) 50 (74.6%) 0.31
α-Glucosidase inhibitor 5 (4.6%) 1 (2.4%) 4 (6.0%) 0.40
Combination treatment Insulin plus OAD 57 (52.8%) 24 (58.5%) 33 (49.2%) 0.35
Insulin plus metformin 5 (4.6%) 2 (4.9%) 3 (4.5%) 1.00
Insulin plus sulfonylurea 56 (51.8%) 24 (58.5%) 32 (47.8%) 0.28
Metformin plus sulfonylurea 23 (21.3%) 9 (21.9%) 14 (20.9%) 0.90
Lipid lowering agents Statins 69 (63.9%) 20 (48.8%) 49 (73.1%) 0.01
Fibrates 4 (3.8%) 1 (2.4%) 3 (4.5%) 1.00
Antihypertensive agents 86 (79.6%) 33 (80.5%) 53 (79.1%) 0.86
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these two explanatory variables in the final multiple lin-
ear regression model to avoid colinearity. We selected 
total cholesterol because its linear correlation with vita-
min D levels was stronger than that of LDL-c. These vari-
ables were then entered into a backward, multiple linear 
regression model (with vitamin D level as the independ-
ent variable); only total cholesterol (unstandardized β 
coefficient = −0.09, p < 0.01) and BMI (unstandardized 
β coefficient = −0.41, p = 0.04) remained independently 
associated with levels of 25(OH)D (Table 3).
Discussion
There were no prior studies on the prevalence of hypo-
vitaminosis D in patients with type 2 diabetes mellitus 
in Brazil. Herein, we showed that hypovitaminosis D 
was present in 62% of patients with type 2 diabetes and 
it was associated with female gender, obesity and dys-
lipidemia. Since the current study was conducted in 
Salvador—Bahia, located at 12°58′S, an area that receives 
adequate sunlight throughout the year, the high preva-
lence of hypovitaminosis D among individuals with type 
2 diabetes encountered herein could be considered unex-
pected. In fact, our findings are comparable to those 
found in diabetic populations of non-tropical regions 
[12–14]. Certain characteristics of our sample may have 
contributed to the high prevalence of hypovitaminosis D.
First, our sample was comprised mostly of non-white 
participants, reflecting the demographics of Bahia, which 
is the Brazilian state with the highest percentage of non-
white population (77.8%). There is evidence that melanin 
can hinder the penetration of sunlight on the skin and 
vitamin D conversion [15].
Second, most participants were overweight or obese. 
The prevalence of obesity was high in our population, 
corroborating the already established link between excess 
weight and type 2 diabetes [1, 16]. Several studies in dia-
betic patients report an association between obesity and 
hypovitaminosis D [14, 17, 18]. Since vitamin D can be 
sequestered in body fat, obese patients tend to have lower 
serum levels. A potential confounder is that obesity is 
also linked to an unhealthier lifestyle, characterized by 
less physical activity, less sun exposure and, hence, lower 
vitamin D levels and worse clinical outcomes [19].
Third, the majority of our participants were women. 
Hoteit et  al. and van der Meer et  al. [20, 21] suggested 
that female gender is an independent predictor of vita-
min D deficiency. This finding is supported by other stud-
ies involving type 2 diabetes [14, 17, 22]. Indeed, female 
gender was an independent predictor of hypovitaminosis 
D in our logistic regression model.
Obesity varies between the sexes and between differ-
ent races and is a recognized risk factor for vitamin D 
deficiency and type 2 diabetes [11, 23–27]. In our study, 
the women had BMIs greater than the men. Perhaps the 
excess body fat in females might have contributed to the 
observed relationship between gender and hypovita-
minosis D.
Fig. 1 Vitamin D status of 108 T2DM patients followed at an outpa-
tient Endocrinology Clinic in Brazil
Fig. 2 Prevalence of hypovitaminosis D: overall and stratified into 
subgroups with significantly higher prevalence
Table 2 Univariate and  multivariate backward logistic 
regression analyses to  identify independent predictors 
of hypovitaminosis D
All 4 variables were entered into the multivariate backward logistic regression 
model but statin use was removed by the system on the final step
Dyslipidemia history of dyslipidemia, Obesity BMI ≥ 30 kg/m2
Variable Univariate p Multivariate p
OR (95% CI) Adjusted OR (95% CI)
Female gender 3.59 (1.49–8.63) 0.00 3.10 (1.16–8.29) 0.02
Dyslipidemia 6.71 (2.48–18.17) 0.00 6.50 (2.24–18.86) <0.01
Statin use 2.86 (1.26–6.47) 0.01
Obesity 2.86 (1.14–7.13) 0.02 2.55 (0.92–7.06) 0.07
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Dyslipidemia was an independent predictor of hypovi-
taminosis D and total cholesterol was inversely correlated 
with levels of 25(OH)D even after controlling for con-
founders. Our data are consistent with other studies in the 
literature that evaluated cardiovascular risk in type 2 dia-
betes patients from sunny regions [17, 28]. Perhaps lipid 
levels might be the intervenient variable that explains 
the link between hypovitaminosis D and cardiovascu-
lar disease in patients with type 2 diabetes. However, the 
literature on this subject is not homogeneous and inter-
ventional studies have failed to demonstrate that raising 
the levels of vitamin D resulted in improvement in the 
lipid profile of type 2 diabetes patients [29–32].
The association between HbA1c and 25(OH)D is con-
troversial. We found a significant weak negative corre-
lation between HbA1C and 25(OH)D, similar to other 
previously published studies [12, 18, 23, 28, 33, 34]. How-
ever glycemic control was not associated with vitamin D 
when we controlled for confounding factors, as verified 
by Luo et al. and Al-Shoumer et al. [35, 36].
The Institute of Medicine suggests that the preva-
lence of hypovitaminosis D in the population has been 
overestimated due to improper use of a high cutoff level 
of 25(OH)D. This Institute alerts that concentrations 
of 25(OH)D above 30  ng/mL were not consistent with 
increased clinical benefit and calls for a consensus to 
determine the appropriate levels of vitamin D to avoid 
Table 3 Simple linear correlation and  multiple lin-
ear regression with  25-hydroxyvitamin D levels as  the 
dependent variable
Variables Simple linear  
correlation
p Multiple linear 
regression
p
Pearson r Unstandardized 
β coefficient
BMI −0.20 0.04 −0.41 0.04
HbA1c −0.22 0.03
Total cholesterol −0.39 0.00 −0.09 <0.01
Triglycerides −0.34 0.00
Microalbuminuria −0.23 0.02
Fig. 3 Simple linear correlation between 25-hydroxyvitamin D and variables indicative of glycemic control and cardiovascular risk. 25(OH)D 
25-hydroxyvitamin D, HbA1c glycated hemoglobin, LDL cholesterol low-density lipoprotein-cholesterol
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under and overtreatment [37]. Considering that our 
mean 25(OH)D was very close to 30 ng/mL, more studies 
are needed to evaluate the adequacy of the current vita-
min D cutoffs in Brazilians with type 2 diabetes. In this 
study, a lower 25(OH)D cutoff for normality would cer-
tainly have resulted in a much lower prevalence of hypo-
vitaminosis D.
Our work has important limitations. At our center, we 
use the chemiluminescence method Diasorin LIAISON 
to assess 25(OH)D status due to convenience, turnaround 
time and cost. Although the gold standard for dosing of 
vitamin D is the LC-MS/MS, several studies have shown 
that Diasorin LIAISON shows acceptable correlation with 
LC-MS/MS [38, 39]. We did not formally collect data on 
financial income, sun exposure time in outdoor activities 
or other characteristics predictive of outdoor behavior. We 
also don’t have data about the season that the blood sam-
ple was drawn but in Salvador-Bahia, temperatures are rel-
atively constant, with about 2500 h of sunshine a year [40]; 
therefore, we believe that season did not play an important 
role in our findings. The observational, cross-sectional 
design precludes any conclusions regarding causality or 
even the direction of the association between vitamin D 
deficiency and cardiovascular risk factors. Moreover, our 
sample is small and of peculiar characteristics, which may 
limit the generalizability of our findings. The relationship 
between HbA1C and serum lipids with 25(OH)D levels 
may have been affected by the use of antidiabetic and lipid-
lowering medications, as these drugs lower HbA1C and 
lipid levels regardless of the vitamin D status; similar stud-
ies in patients with early type 2 diabetes before initiating 
treatment could help clarify this relationship.
Conclusion
In conclusion, we have identified a high prevalence (62%) 
of hypovitaminosis D among Brazilians with type 2 dia-
betes and an association between hypovitaminosis D 
with female gender, obesity and dyslipidemia. Our data 
indicates that availability of adequate sunlight alone is 
not sufficient for the prevention of vitamin D deficiency 
and raises awareness of hypovitaminosis D in the diabetic 
population, regardless of geographic location.
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